Akebia Therapeutics Inc. Stock
Akebia Therapeutics Inc. Stock
A loss of -2.340% shows a downward development for Akebia Therapeutics Inc..
Akebia Therapeutics Inc. is currently one of the favorites of our community with 8 Buy predictions and no Sell predictions.
Based on the current price of 0.75 € the target price of 4 € shows a potential of 431.77% for Akebia Therapeutics Inc. which would more than double the current price.
For the coming years our community has positive and negative things to say abot the Akebia Therapeutics Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "General Risks" there were negative voices in the community.
Pros and Cons of Akebia Therapeutics Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
B****
?
C******** o* t** e**********
Cons
?
S********** s********
?
G***** c******* t* c**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Akebia Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Akebia Therapeutics Inc. | -2.340% | -32.633% | -36.926% | -72.565% | -43.238% | -34.042% | -65.892% |
| Heron Therapeutics Inc. | 2.340% | -32.607% | -20.601% | -75.641% | -73.914% | -80.497% | -96.899% |
| Evolus Inc | -0.400% | 27.435% | 22.133% | 31.811% | 28.183% | -21.506% | -21.506% |
| Rhythm Pharmaceuticals | -0.990% | 6.878% | 7.447% | 24.691% | 8.021% | 313.934% | 763.248% |
Comments
Akebia Therapeutics (AKBA) had its "buy" rating reaffirmed by HC Wainwright.
Show more
Ratings data for AKBA provided by MarketBeat
Akebia Therapeutics (AKBA) had its "buy" rating reaffirmed by HC Wainwright. They now have a $6.00 price target on the stock.
Show more
Ratings data for AKBA provided by MarketBeat
Akebia Therapeutics (AKBA) had its "buy" rating reaffirmed by BTIG Research. They now have a $4.00 price target on the stock.
Show more
Ratings data for AKBA provided by MarketBeat
News
Akebia Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Akebia Therapeutics, Inc.? Here are five stocks we like better.
- Vafseo revenue rose sharply to $21.3 million in Q2 2026, up 34% sequentially and 60% year over year
Akebia Therapeutics Sees Vafseo Uptake Rising as Access and Pipeline Milestones Near
Key Points
- Interested in Akebia Therapeutics, Inc.? Here are five stocks we like better.
- Vafseo uptake is improving, with Akebia saying the number of prescribing physicians rose 28% to about